FDA Halts Bitopertin Approval, Demanding Clearer Patient Benefit

WATERTOWN, Mass. – February 13, 2026 – Hopes for an expedited approval of a new treatment for a rare and painful genetic disorder were dashed today, as the U.S. Food and Drug Administration (FDA) declined to approve Disc Medicine’s oral drug, bitopertin. The agency issued a Complete Response Letter (CRL) for the New Drug Application, effectively sending the company back to the drawing board to gather more definitive clinical evidence.

Bitopertin was under review for the treatment of erythropoietic protoporphyria (EPP), a condition that causes severe pain upon exposure to sunlight. While the FDA acknowledged the drug's success in reducing a key biomarker associated with the disease, it concluded that the existing data did not sufficiently prove that this reduction translated into a tangible clinical benefit for patients—specifically, the ability to spend more time in the sun without pain. The decision represents a significant delay for patients and a strategic pivot for Disc Medicine, which must now rely on a larger, ongoing study to win regulatory acceptance.

A Higher Bar for Biomarkers

The FDA's decision hinges on the complex issue of surrogate endpoints in drug approval. For its accelerated approval application, Disc Medicine relied on data from its AURORA and BEACON trials, which showed that bitopertin significantly lowered levels of whole blood metal-free protoporphyrin IX (PPIX). In EPP, the accumulation of PPIX is what causes the extreme photosensitivity. The company argued that reducing this toxic substance was “reasonably likely to predict a clinical benefit.”

In its response, the FDA agreed on the first point: bitopertin does indeed lower PPIX. However, the agency was not convinced on the second, more critical point. The CRL stated that the trials failed to show a clear association between the percentage change in PPIX and the trial's endpoints related to sunlight exposure. This highlights a broader, more rigorous stance the FDA has been taking on the accelerated approval pathway, demanding a stronger, more direct link between a change in a biomarker and a meaningful improvement in a patient's daily life.

Despite what Disc Medicine described as “strong mechanistic and biological plausibility” for using PPIX as a biomarker, the agency is signaling that plausibility alone is not enough. It needs to see the data, and for bitopertin, that data will now have to come from the ongoing Phase 3 APOLLO study.

Hope on Hold for Patients

For the EPP patient community, the delay is a significant blow. EPP is a debilitating condition that forces individuals to live in fear of the sun. Exposure to visible light, even through window glass, can trigger excruciating burning pain, redness, and swelling that can last for days. The impact on quality of life is profound, leading to social isolation and a constant state of anxiety.

Currently, treatment options are scarce. The only FDA-approved drug is afamelanotide (Scenesse®), which is administered as a subcutaneous implant every two months and is only approved for adults. It helps by increasing skin pigmentation but is not a disease-modifying treatment. For children with protoporphyrias, there are no approved pharmacological options, leaving them and their families to rely solely on extreme sun avoidance and protective clothing.

Bitopertin, as a potential first-in-class oral therapy designed to inhibit the production of the problematic PPIX, represented a new paradigm and a source of immense hope. The prospect of a daily pill that could fundamentally alter the disease's course had generated considerable enthusiasm. This CRL means the wait for such a potentially life-changing therapy will be significantly longer.

Navigating the Setback

In response to the news, Disc Medicine's stock (NASDAQ:IRON) plunged over 21%, reflecting investor disappointment with the derailed accelerated approval strategy. However, the company's leadership is projecting confidence and emphasizing its financial stability and the clear path forward.

“We are committed to delivering bitopertin to patients, knowing how critical this potentially disease-modifying therapy is to the EPP community,” said John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, in a statement. “While our efforts at utilizing expedited pathways to get bitopertin to patients quickly have not come to fruition, we are continuing to pursue all avenues in support of FDA approval.”

Financially, Disc Medicine appears well-equipped to handle the delay. The company reported approximately $791 million in cash and equivalents at the end of 2025, providing a cash runway projected to last into 2029. This robust financial footing gives it the stability to see the APOLLO trial through to completion without immediate financial pressure. The company plans to request a Type A meeting with the FDA to discuss the path forward, but all hopes now rest on the success of its next major study.

All Eyes on the APOLLO Trial

The FDA explicitly pointed to the ongoing Phase 3 APOLLO study as the potential basis for a traditional approval. This randomized, double-blind, placebo-controlled trial is designed specifically to answer the questions the FDA raised. Its primary endpoint is the average monthly time patients can spend in sunlight without pain, a direct measure of clinical benefit that the previous trials lacked.

The study, which is also enrolling patients with the related X-Linked Protoporphyria (XLP), has seen strong enthusiasm from patients and physicians, allowing Disc to complete enrollment in March 2026, several months ahead of schedule. Topline data from APOLLO are now anticipated in the fourth quarter of 2026.

If the results are positive and demonstrate a clear link between bitopertin and increased sunlight tolerance, Disc plans to file a response to the CRL. An updated decision from the FDA could then come by mid-2027. While this timeline is a delay, the APOLLO trial offers a definitive, albeit longer, path to approval. Its success is now critical, not only to bring bitopertin to market but also to position it within a competitive landscape that includes other emerging oral therapies like Mitsubishi Tanabe Pharma's dersimelagon, which is also in late-stage development.